Cargando…
The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling
BACKGROUND: Comprehensive genomic profiling has become standard clinical practice in the management of advanced lung cancer. In addition to tissue and plasma, other body fluids are also being actively explored as alternative sources of tumor DNA. This study investigated the utility of induced sputum...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096409/ https://www.ncbi.nlm.nih.gov/pubmed/35571392 http://dx.doi.org/10.21037/atm-22-1297 |
_version_ | 1784705972175896576 |
---|---|
author | Qin, Ling Guo, Ting Yang, Huaping Deng, Pengbo Gu, Qihua Liu, Chi Wu, Mengping Lizaso, Analyn Li, Bing Zhang, Sa Chen, Zhiqiu Hu, Chengping |
author_facet | Qin, Ling Guo, Ting Yang, Huaping Deng, Pengbo Gu, Qihua Liu, Chi Wu, Mengping Lizaso, Analyn Li, Bing Zhang, Sa Chen, Zhiqiu Hu, Chengping |
author_sort | Qin, Ling |
collection | PubMed |
description | BACKGROUND: Comprehensive genomic profiling has become standard clinical practice in the management of advanced lung cancer. In addition to tissue and plasma, other body fluids are also being actively explored as alternative sources of tumor DNA. This study investigated the utility of induced sputum obtained from patients with non-small-cell lung cancer (NSCLC) for somatic variation profiling. METHODS: Our study included 41 treatment-naïve patients diagnosed with locally advanced to advanced NSCLC between October 2018 and June 2019. Capture-based targeted sequencing was performed on matched tumor, plasma, and induced sputum samples of 41 patients using a 168-gene panel. We analyzed the somatic variations detected from each sample type and the concordance of variations detected between matched samples. The concordance rate was defined as the proportion of the total number of variations detected from one sample type relative to the reference sample type. RESULTS: Comparative analysis on the somatic variation detection using matched tumor samples as a reference revealed detection rates of 76.9% for plasma, 72.4% for sputum-supernatant, and 65.7% for sputum-sediment samples. Plasma, sputum-supernatant, and sputum-sediment achieved positive predictive values of 73.3%, 80.4%, and 55.6% and sensitivities of 50.0%, 36.9%, 31.3%, respectively, relative to tumor samples for 168 genes. Sputum-supernatants had significantly higher concordance rates relative to matched tumor samples (69.2% vs. 37.8%; P=0.031) and maximum allelic fraction (P<0.001) than their matched sputum-sediments. Sputum-supernatants had comparable detection rates (71.4% vs. 67.9%; P=1.00) but with significantly higher maximum allelic fraction than their matched plasma samples (P=0.003). Furthermore, sputum-supernatant from smokers had a significantly higher maximum allelic fraction than sputum-supernatant from non-smokers (P=0.021). CONCLUSIONS: Our study demonstrated that supernatant fraction from induced sputum is a better sampling source than its sediment and performs comparably to plasma samples. Induced sputum from NSCLC patients could serve as an alternative media for next-generation sequencing (NGS)-based somatic variation profiling. |
format | Online Article Text |
id | pubmed-9096409 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-90964092022-05-13 The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling Qin, Ling Guo, Ting Yang, Huaping Deng, Pengbo Gu, Qihua Liu, Chi Wu, Mengping Lizaso, Analyn Li, Bing Zhang, Sa Chen, Zhiqiu Hu, Chengping Ann Transl Med Original Article BACKGROUND: Comprehensive genomic profiling has become standard clinical practice in the management of advanced lung cancer. In addition to tissue and plasma, other body fluids are also being actively explored as alternative sources of tumor DNA. This study investigated the utility of induced sputum obtained from patients with non-small-cell lung cancer (NSCLC) for somatic variation profiling. METHODS: Our study included 41 treatment-naïve patients diagnosed with locally advanced to advanced NSCLC between October 2018 and June 2019. Capture-based targeted sequencing was performed on matched tumor, plasma, and induced sputum samples of 41 patients using a 168-gene panel. We analyzed the somatic variations detected from each sample type and the concordance of variations detected between matched samples. The concordance rate was defined as the proportion of the total number of variations detected from one sample type relative to the reference sample type. RESULTS: Comparative analysis on the somatic variation detection using matched tumor samples as a reference revealed detection rates of 76.9% for plasma, 72.4% for sputum-supernatant, and 65.7% for sputum-sediment samples. Plasma, sputum-supernatant, and sputum-sediment achieved positive predictive values of 73.3%, 80.4%, and 55.6% and sensitivities of 50.0%, 36.9%, 31.3%, respectively, relative to tumor samples for 168 genes. Sputum-supernatants had significantly higher concordance rates relative to matched tumor samples (69.2% vs. 37.8%; P=0.031) and maximum allelic fraction (P<0.001) than their matched sputum-sediments. Sputum-supernatants had comparable detection rates (71.4% vs. 67.9%; P=1.00) but with significantly higher maximum allelic fraction than their matched plasma samples (P=0.003). Furthermore, sputum-supernatant from smokers had a significantly higher maximum allelic fraction than sputum-supernatant from non-smokers (P=0.021). CONCLUSIONS: Our study demonstrated that supernatant fraction from induced sputum is a better sampling source than its sediment and performs comparably to plasma samples. Induced sputum from NSCLC patients could serve as an alternative media for next-generation sequencing (NGS)-based somatic variation profiling. AME Publishing Company 2022-04 /pmc/articles/PMC9096409/ /pubmed/35571392 http://dx.doi.org/10.21037/atm-22-1297 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Qin, Ling Guo, Ting Yang, Huaping Deng, Pengbo Gu, Qihua Liu, Chi Wu, Mengping Lizaso, Analyn Li, Bing Zhang, Sa Chen, Zhiqiu Hu, Chengping The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling |
title | The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling |
title_full | The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling |
title_fullStr | The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling |
title_full_unstemmed | The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling |
title_short | The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling |
title_sort | utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096409/ https://www.ncbi.nlm.nih.gov/pubmed/35571392 http://dx.doi.org/10.21037/atm-22-1297 |
work_keys_str_mv | AT qinling theutilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT guoting theutilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT yanghuaping theutilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT dengpengbo theutilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT guqihua theutilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT liuchi theutilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT wumengping theutilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT lizasoanalyn theutilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT libing theutilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT zhangsa theutilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT chenzhiqiu theutilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT huchengping theutilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT qinling utilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT guoting utilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT yanghuaping utilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT dengpengbo utilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT guqihua utilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT liuchi utilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT wumengping utilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT lizasoanalyn utilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT libing utilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT zhangsa utilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT chenzhiqiu utilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling AT huchengping utilityofsputumsupernatantasanalternativeliquidbiopsyspecimenfornextgenerationsequencingbasedsomaticvariationprofiling |